Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Mednax

Related MD
US Stock Futures Surge Ahead Of Federal Budget
UPDATE: MEDNAX Announces Data Milestone for Pediatrix Segment

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Mednax (NYSE: MD), and raised its price target from $81.00 to $88.00.

Jefferies noted, “MD is one of our top picks given our belief that the company's push to aggressively expand its anesthesiology business (which we expect mgmt to highlight at today's analyst day) will drive robust growth over the next several years that is not yet adequately reflected in the stock's valuation. Our positive bias is also driven by MD's highly defensive (i.e., benign) reimbursement outlook. Reiterate Buy/PT to $88.”

Mednax closed on Tuesday at $75.29.

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (MD)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters